Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
This phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Recurrent Childhood Anaplastic Astrocytoma
Recurrent Childhood Anaplastic Ependymoma
Recurrent Childhood Diffuse Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Giant Cell Glioblastoma
Recurrent Childhood Glioblastoma
Recurrent Childhood Gliosarcoma
Recurrent Childhood Medulloblastoma
Recurrent Childhood Oligodendroglioma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor (PNET)
Recurrent Childhood Brain Stem Glioma
Drug: imetelstat sodium
Other: laboratory biomarker analysis
Other: pharmacological study
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and Diffuse Intrinsic Pontine Glioma|
- Percentage of subjects with telomerase-positive archival tumors who demonstrate at least 50% reduction in telomerase activity (Molecular biology study) [ Time Frame: Up to 30 days ] [ Designated as safety issue: No ]Summarized and described via summary statistics and plots.
- Stratum-specific objective response (CR+PR) rate (Phase II) [ Time Frame: 6 months ] [ Designated as safety issue: No ]For each stratum separately exact confidence interval estimates will be provided for the true, unknown rates of objective response. Estimated by cumulative incidence functions.
- Quantitative assessments of hTERT mRNA and TERC RNA levels (Molecular biology study) [ Time Frame: Up to 30 days ] [ Designated as safety issue: No ]Summarized and described via summary statistics and plots. Descriptive statistics, plots and, if adequate data are available to make such models viable, mixed effects models and changes in telomerase activity in peripheral blood mononuclear cells (PBMNCs) longitudinally will be explored.
- Stratum-specific progression-free survival (PFS) (Phase II) [ Time Frame: From the date of initial treatment to the earliest date of disease progression, second malignancy or death for subjects who fail; and to the date of last contact for subjects who remain at risk for failure, assessed up to 3 years ] [ Designated as safety issue: No ]Kaplan-Meier estimates of distributions of survival and PFS for all eligible subjects who received at least one dose of imetelstat will be provided separately. Similarly, Cox regression models may be used to look for associations between PK parameters and PFS separately in each stratum in the Phase II study.
- Quantitative assessment of telomerase activity by TRAP and telomere length by Southern blot (Molecular biology and Phase II studies) [ Time Frame: Up to 30 days ] [ Designated as safety issue: No ]95% confidence intervals will be estimated. Summarized and described via summary statistics and plots.
- ALT use by TRF analysis/Southern blot, telomere-specific FISH and localization of ATRX/DAXX (Molecular biology and Phase II studies) [ Time Frame: Up to 30 days ] [ Designated as safety issue: No ]Summarized and described via summary statistics and plots.
- Quantitative MRI parameters of tumors prior to and after treatment with imetelstat (Molecular biology and Phase II studies) [ Time Frame: Up to 30 days ] [ Designated as safety issue: No ]Summarized and described via summary statistics and plots.
|Study Start Date:||March 2013|
|Estimated Primary Completion Date:||February 2016 (Final data collection date for primary outcome measure)|
Experimental: Treatment (imetelstat sodium)
Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.
Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Drug: imetelstat sodium
Other Names:Other: laboratory biomarker analysis
Correlative studiesOther: pharmacological study
Other Name: pharmacological studies
Show Detailed Description
|United States, California|
|Childrens Hospital Los Angeles||Recruiting|
|Los Angeles, California, United States, 90027-0700|
|Contact: Girish Dhall, MD 323-361-8589 firstname.lastname@example.org|
|Lucile Packard Children's Hospital at Stanford University Medical Center||Recruiting|
|Palo Alto, California, United States, 94304|
|Contact: Paul G. Fisher, MD, MHS 650-497-8953 email@example.com|
|United States, District of Columbia|
|Children's National Medical Center||Recruiting|
|Washington, District of Columbia, United States, 20010-2970|
|Contact: Roger J. Packer, MD 202-884-2120 firstname.lastname@example.org|
|United States, Illinois|
|Lurie Children's Hospital- Chicago||Recruiting|
|Chicago, Illinois, United States, 60614|
|Contact: Stewart Goldman, MD 773-880-4562|
|United States, Maryland|
|NCI - Pediatric Oncology Branch||Not yet recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: Katherine Warren, MD 301-435-4683|
|United States, New York|
|Memorial Sloan-Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Ira Dunkel, MD 212-639-2153 email@example.com|
|United States, North Carolina|
|Duke Comprehensive Cancer Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Contact: Sri Gururangan, MD 919-668-6288 firstname.lastname@example.org|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Recruiting|
|Cincinnati, Ohio, United States, 45229-3039|
|Contact: Clinical Trials Office - Cincinnati Children's Hospital Medica 513-636-2799|
|United States, Pennsylvania|
|Children's Hospital of Pittsburgh||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15213|
|Contact: Ian F. Pollack, MD 412-692-5881 email@example.com|
|United States, Tennessee|
|Saint Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105-2794|
|Contact: Alberto Broniscer 901-595-4925 firstname.lastname@example.org|
|United States, Texas|
|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital||Recruiting|
|Houston, Texas, United States, 77030-2399|
|Contact: Murali M. Chintagumpala, MD 832-822-4266|
|Principal Investigator:||Maryam Fouladi||Pediatric Brain Tumor Consortium|